Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.

ABSTRACT:

Context

In the Women's Health Initiative randomized, placebo-controlled trial of estrogen plus progestin, after a mean intervention time of 5.6 (SD, 1.3) years (range, 3.7-8.6 years) and a mean follow-up of 7.9 (SD, 1.4) years, breast cancer incidence was increased among women who received combined hormone therapy. Breast cancer mortality among participants in the trial has not been previously reported.

Objective

To determine the effects of therapy with estrogen plus progestin on cumulative breast cancer incidence and mortality after a total mean follow-up of 11.0 (SD, 2.7) years, through August 14, 2009.

Design, setting, and participants

A total of 16,608 postmenopausal women aged 50 to 79 years with no prior hysterectomy from 40 US clinical centers were randomly ass

SUBMITTER: Chlebowski RT 

PROVIDER: S-EPMC5142300 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature